Analysts are on the Bearish side about DexCom, Inc. (NASDAQ:DXCM) this week.

DexCom, Inc. (NASDAQ:DXCM) Logo
Investors sentiment decreased to 1 in Q2 2019. Its down 0.07, from 1.07 in 2019Q1. It worsened, as 51 investors sold DexCom, Inc. shares while 115 reduced holdings. 50 funds opened positions while 116 raised stakes. 84.91 million shares or 12.27% less from 96.78 million shares in 2019Q1 were reported.
Quantitative Invest Mgmt Limited Liability has invested 0.44% in DexCom, Inc. (NASDAQ:DXCM). Rafferty Asset Management Limited has invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). 3,093 were accumulated by First Republic Management. & stated it has 190 shares. 36,338 were accumulated by Dafna Cap Management Ltd Llc. Employees Retirement Association Of Colorado stated it has 0.01% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Metropolitan Life Insurance New York reported 6,437 shares stake. 99,007 are held by D E Shaw. Robeco Institutional Asset Mngmt Bv accumulated 216,214 shares or 0.11% of the stock. Citigroup reported 0% stake. Loring Wolcott & Coolidge Fiduciary Advsrs Limited Liability Partnership Ma reported 0% in DexCom, Inc. (NASDAQ:DXCM). Parkside Fincl Commercial Bank holds 158 shares. Trexquant Ltd Partnership accumulated 23,010 shares or 0.31% of the stock. Private Ocean Limited Com accumulated 300 shares or 0.01% of the stock. Ls Ltd Llc holds 0.01% or 560 shares in its portfolio.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 6 analysts covering DexCom (NASDAQ:DXCM), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. DexCom has $19500 highest and $15000 lowest target. $177.43’s average target is 14.21% above currents $155.35 stock price. DexCom had 9 analyst reports since April 30, 2019 according to SRatingsIntel. The firm has “Overweight” rating given on Thursday, August 1 by JP Morgan. As per Thursday, August 1, the company rating was maintained by Bank of America. The firm has “Outperform” rating by Robert W. Baird given on Thursday, August 1. Raymond James maintained it with “Outperform” rating and $17200 target in Thursday, August 1 report. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Outperform” rating by Robert W. Baird on Thursday, August 29. The rating was maintained by BMO Capital Markets with “Outperform” on Tuesday, September 3. The stock has “Neutral” rating by UBS on Thursday, August 1. Below is a list of DexCom, Inc. (NASDAQ:DXCM) latest ratings and price target changes.

20/09/2019 Broker: BidaskScore Rating: Buy Upgrade
03/09/2019 Broker: BMO Capital Markets Rating: Outperform Old Target: $180.0000 New Target: $190.0000 Maintain
29/08/2019 Broker: Robert W. Baird Rating: Outperform Old Target: $186.0000 New Target: $195.0000 Maintain
01/08/2019 Broker: Bank of America Rating: Buy Old Target: $162.0000 New Target: $185.0000 Maintain
01/08/2019 Broker: Robert W. Baird Rating: Outperform Old Target: $180.0000 New Target: $186.0000 Maintain
01/08/2019 Broker: JP Morgan Rating: Overweight Old Target: $170.0000 New Target: $190.0000 Maintain
01/08/2019 Broker: UBS Rating: Neutral Old Target: $140.0000 New Target: $160.0000 Maintain
01/08/2019 Broker: Raymond James Rating: Outperform Old Target: $150.0000 New Target: $172.0000 Maintain
30/04/2019 Broker: Inc. – Common Stock Rating: Ubs New Target: $150.0000 140.0000

The stock increased 0.58% or $0.89 during the last trading session, reaching $155.35. About 385,335 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 67.97% since October 12, 2018 and is uptrending. It has outperformed by 67.97% the S&P500.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $14.17 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

More notable recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Seekingalpha.com which released: “DexCom Still Has Significant Upside Potential – Seeking Alpha” on September 25, 2019, also Seekingalpha.com with their article: “DexCom: High Growth, Intense Competition, Extreme Valuation – Seeking Alpha” published on June 28, 2019, Streetinsider.com published: “DexCom (DXCM) Names Bridgette Heller to Board – StreetInsider.com” on September 17, 2019. More interesting news about DexCom, Inc. (NASDAQ:DXCM) were released by: Seekingalpha.com and their article: “Why DexCom Faces 45-60% Downside Risk From Abbot’s New Libre 2 Product – Seeking Alpha” published on March 22, 2019 as well as Nasdaq.com‘s news article titled: “DXCM Crosses Below Key Moving Average Level – Nasdaq” with publication date: March 25, 2019.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.